Global Information
회사소개 | 문의 | 위시리스트

세계의 부정맥 치료제 시장(2019-2023년)

Global Cardiac Arrhythmias Therapeutics Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 07월 상품 코드 900601
페이지 정보 영문 130 Pages
가격
US $ 2,500 ₩ 3,001,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,601,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,802,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,002,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 부정맥 치료제 시장(2019-2023년) Global Cardiac Arrhythmias Therapeutics Market 2019-2023
발행일 : 2019년 07월 페이지 정보 : 영문 130 Pages

세계 부정맥 치료제 시장은 2018년 경구 부정맥 치료제의 낮은 단가, 편리한 사용, 무통증, 서방효과 등의 요인에 의해 경구약 부문이 높은 시장 점유율을 획득했고, 이러한 경향은 예측 기간 동안 계속될 것으로 예상됩니다. 또 부정맥 치료제 시장은 혈전증 유병률 증가, 정확한 진단 방법의 이용 가능성, 심혈관질환에 관한 의식 고양 등이 성장 가속화 요인이 되어 예측기간 중 4% 이상의 연평균 복합 성장률(CAGR)로 확대될 전망입니다. 하지만 부정맥 치료제에 관련된 블랙박스 경고, 대체 제품의 입수 가능성, 엄격한 규제 환경이 예측기간 중 부정맥 치료제 업계의 성장을 방해할 가능성이 있습니다.

세계의 부정맥 치료제(Cardiac Arrhythmias Therapeutics) 시장에 대해 조사 분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인과 과제, 시장 기회 분석, 주요 벤더 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 주요 요약

제2장 조사 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환산율

제3장 시장 상황

  • 시장 생태계
  • 시장의 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대용품의 위협
  • 경쟁사의 위협
  • 시장 현황

제6장 시장 세분화 : 용도별

  • 시장 세분화 : 용도별
  • 용도별 비교 : 시장 규모 및 예측(2018-2023년)
  • 경구약
  • 정맥주사
  • 시장 기회 : 용도별

제7장 고객 상황

제8장 지역별 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제9장 의사결정 프레임워크

제10장 성장요인과 과제

  • 시장 성장요인
  • 시장의 과제

제11장 시장 동향

  • AF의 심박수를 제어하는 유전자 치료의 등장
  • 부정맥의 조기 발견을 가능하게 하는 기술적 진보
  • 벤더의 연구개발 노력 진전

제12장 벤더 상황

  • 개요
  • 파괴적 혁신
  • 경쟁 시나리오

제13장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

제14장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제15장 TECHNAVIO에 대해

LSH 19.08.13

About this market

Cardiac arrhythmias therapeutics are pharmaceutical agents that are used to normalize the issue of cardiac arrhythmia. Technavio's cardiac arrhythmias therapeutics market analysis considers sales from both oral and intravenous applications. Our analysis also considers the sales of cardiac arrhythmias therapeutics in North America, Europe, Asia and the rest of the world (ROW). In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as Low cost, easy to consume, no pain, extended-release effect of oral arrhythmias therapeutics will play a significant role in the oral segment to maintain its market position. Also, our global cardiac arrhythmias therapeutics market report also looks at factors such as the growing prevalence of thrombosis, availability of precise diagnostic methods, rising awareness about cardiovascular diseases. However, black box warning associated with cardiac arrhythmias therapeutics, availability of substitute products, stringent regulatory environment may hamper the growth of the cardiac arrhythmias therapeutics industry over the forecast period.

Overview

Availability of precise diagnostic methods

The availability of precise diagnostic methods, like electrocardiogram (ECG) Hotter monitors, event monitors, stress IQ tests, echocardiogram, cardiac catheterization, electrophysiology study (EPS), and head-up tiff table tests have led to increase in the diagnosis rate of cardiac arrhythmias, thus contributing to increased prescription of therapeutics for cardiac arrhythmias. Such factors will lead to the expansion of the global cardiac arrhythmias therapeutics market at a CAGR of over 4% during the forecast period.

The advent of gene therapy to control ventricular rate in AF

The current treatment therapy for AF involves the use of antiarrhythmic drugs to sustain the sinus rhythm or drugs that can curb the conduction in the atrioventricular (AV) node in order to control the ventricular rate. The medication therapy used for the treatment of arrhythmia exerts its pharmacological effect by targeting the conduction properties of the AV node- by suppressing the calcium current or by altering the cholinergic and adrenergic tone. Therefore, the global cardiac arrhythmias therapeutics market presents an urgent need for the development of biological drugs, which can target the gene and thus, improve cardiac functioning. Ongoing research in this area is expected to have a positive impact on market growth during the forecast period.

For the detailed list of factors that will drive the global cardiac arrhythmias therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global cardiac arrhythmias therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cardiac arrhythmias therapeutics manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Also, the cardiac arrhythmias therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Oral - Market size and forecast 2018-2023
  • Intravenous - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • The advent of gene therapy to control ventricular rate in AF
  • Technological advances enabling the early detection of cardiac arrhythmias
  • Growing R&D efforts by vendors

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Application - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Intravenous - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Intravenous - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by application
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Diagnostic methods
  • Exhibit 43: Side-effects of cardiac arrhythmias therapeutics
  • Exhibit 44: Substitute products to cardiac arrhythmias therapeutics
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Bayer AG - Vendor overview
  • Exhibit 52: Bayer AG - Business segments
  • Exhibit 53: Bayer AG - Organizational developments
  • Exhibit 54: Bayer AG - Geographic focus
  • Exhibit 55: Bayer AG - Segment focus
  • Exhibit 56: Bayer AG - Key offerings
  • Exhibit 57: Bayer AG - Key customers
  • Exhibit 58: Eli Lilly and Co. - Vendor overview
  • Exhibit 59: Eli Lilly and Co. - Business segments
  • Exhibit 60: Eli Lilly and Co. - Organizational developments
  • Exhibit 61: Eli Lilly and Co. - Geographic focus
  • Exhibit 62: Eli Lilly and Co. - Segment focus
  • Exhibit 63: Eli Lilly and Co. - Key offerings
  • Exhibit 64: Eli Lilly and Co. - Key customers
  • Exhibit 65: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 66: GlaxoSmithKline Plc - Business segments
  • Exhibit 67: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 68: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 69: GlaxoSmithKline Plc - Segment focus
  • Exhibit 70: GlaxoSmithKline Plc - Key offerings
  • Exhibit 71: GlaxoSmithKline Plc - Key customers
  • Exhibit 72: Pfizer Inc. - Vendor overview
  • Exhibit 73: Pfizer Inc. - Business segments
  • Exhibit 74: Pfizer Inc. - Organizational developments
  • Exhibit 75: Pfizer Inc. - Geographic focus
  • Exhibit 76: Pfizer Inc. - Segment focus
  • Exhibit 77: Pfizer Inc. - Key offerings
  • Exhibit 78: Pfizer Inc. - Key customers
  • Exhibit 79: Sanofi - Vendor overview
  • Exhibit 80: Sanofi - Business segments
  • Exhibit 81: Sanofi - Organizational developments
  • Exhibit 82: Sanofi - Geographic focus
  • Exhibit 83: Sanofi - Segment focus
  • Exhibit 84: Sanofi - Key offerings
  • Exhibit 85: Sanofi - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q